Compass Therapeutics, Inc. (CMPX)
CMPX moved a median of +0.05% 30 minutes after news, and 0.00% by the close. How CMPX actually reacts to news — the realized, point-in-time move the market made, measured across 249 labeled events over the last three years with zero look-ahead.
CMPX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 248 |
| 30-min | +0.05% | 51% | 249 |
| 60-min | +0.53% | 59% | 249 |
| to close | 0.00% | 46% | 248 |
| Middle 50% of CMPX reactions | -1.16% to +1.65% |
|---|---|
| Median reaction (30-min) | +0.05% |
| Measured reactions | 249 |
Half of all Compass Therapeutics, Inc. news events land between -1.16% and +1.65% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CMPX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.65% | 64% | -2.29% |
| Coverage initiations | 31 | -3.29% | 45% | -2.04% |
| Rating reiterations | 67 | -0.23% | 36% | 0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CMPX ranks against every other measured name →
That’s how CMPX usually reacts — get an email when it moves on news →Email me when CMPX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CMPX's baseline. Nothing else.
Recent CMPX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.60% | +4.27% | |
| Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback | Press release | GlobeNewswire | +2.78% | -1.59% | |
| Form 8-K Compass Therapeutics, For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +2.78% | -1.59% | |
| Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.52% | +3.11% | |
| Form 10-Q Compass Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.52% | +3.11% | |
| Form 8-K Compass Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -0.52% | +3.11% | |
| Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 | Press release | GlobeNewswire | +0.47% | -2.61% | |
| Form 8-K Compass Therapeutics, For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | +3.65% | |
| A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs | Press release | Canada Newswire | -0.23% | +1.39% | |
| Form 8-K Compass Therapeutics, For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +2.21% | +0.98% | |
| Form 8-K Compass Therapeutics, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | +1.50% | |
| Compass Therapeutics to Participate in Upcoming June Investor Events | Press release | GlobeNewswire | +0.45% | +7.59% | |
| Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +2.36% | +8.38% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.25% | -0.50% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.10% | +4.40% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +1.89% | +0.81% | |
| Compass Therapeutics to Participate in Upcoming May Investor Events | Press release | GlobeNewswire | +1.15% | +2.19% | |
| Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -2.19% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutics, Inc. (CMPX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.05% | -1.84% | |
| Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.83% | +0.52% | |
| Form 10-Q Compass Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.83% | +0.52% | |
| Form 8-K Compass Therapeutics, For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -2.83% | +0.52% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.26% | +0.78% | |
| Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.61% | -2.02% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.14% | +4.12% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutics, Inc. (CMPX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.56% | +0.56% | |
| Form ARS Compass Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -4.47% | -12.11% | |
| Form DEF 14A Compass Therapeutics, For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -4.47% | -12.11% | |
| Form DEFA14A Compass Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -4.47% | -12.11% | |
| Form 8-K Compass Therapeutics, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +7.89% | +1.13% | |
| Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer | Press release | GlobeNewswire | +7.89% | +1.13% | |
| Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer | Press release | GlobeNewswire | +7.89% | +1.13% | |
| Form S-8 Compass Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -1.00% | -5.64% | |
| Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.08% | +0.00% | |
| Form 10-K Compass Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.08% | +0.00% | |
| Form 8-K Compass Therapeutics, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +1.08% | +0.00% | |
| Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight | Press release | PR Newswire | -0.27% | +0.55% | |
| Form EFFECT Compass Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -2.59% | -4.44% | |
| Compass Therapeutics Provides Corporate Update | Press release | GlobeNewswire | -0.41% | +0.00% | |
| Form 8-K Compass Therapeutics, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | +0.00% | |
| Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.41% | +0.00% | |
| Compass Therapeutics Announces Key Leadership Appointments | Press release | GlobeNewswire | -2.98% | -6.90% | |
| Form DEL AM Compass Therapeutics, | SEC filing · Form DEL | SEC EDGAR | +0.00% | -3.54% | |
| Form S-3 Compass Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -2.05% | +0.00% | |
| Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference | Press release | GlobeNewswire | +0.10% | -5.52% | |
| Compass Therapeutics to Participate in Upcoming December Investor Events | Press release | GlobeNewswire | -0.20% | +0.40% | |
| Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.26% | +0.00% | |
| Form 10-Q Compass Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.26% | +0.00% | |
| Form 8-K Compass Therapeutics, For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -0.26% | +0.00% | |
| Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | Press release | GlobeNewswire | +1.08% | +2.71% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CMPX section they belong to.
Where else CMPX is measured.
CMPX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Compass Therapeutics, Inc.'s median reaction calculated?
Every labeled CMPX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 249 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of CMPX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CMPX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.